Top

Pituitary

Published in:

01-10-2015

MicroRNA involvement in a metastatic non-functioning pituitary carcinoma

Authors: Zhenqing Wei, Cuiqi Zhou, Mei Liu, Yong Yao, Jian Sun, Jianqi Xiao, Wenbin Ma, Huijuan Zhu, Renzhi Wang

Published in: Pituitary | Issue 5/2015

Abstract

Purpose

Pituitary carcinomas are extremely rare neoplasms, and molecular events leading to malignant pituitary transformation are largely unknown. Enhanced understanding of molecular mechanisms driving malignant pituitary progression would be beneficial for pituitary carcinoma diagnosis and treatment.

Methods

Differential microRNA expression in paired primary and metastatic pituitary carcinoma specimens were detected using high-throughput human microRNA microarrays and TaqMan microRNA arrays. Three of significantly deregulated miRNAs were further confirmed using quantitative real-time PCR in the metastatic carcinoma, six atypical pituitary adenomas and eight typical pituitary adenomas. Target genes of microRNAs were bioinformatically predicated and verified in vitro by Western blotting and real-time PCR and in vivo by immunohistochemistry respectively.

Results

We present a case of a 50-year-old woman harboring non-functioning pituitary carcinoma with multiple intracranial metastases, and identified up-regulation of miR-20a, miR-106b and miR-17-5p in the metastatic carcinoma as compared to the primary neoplasm. Furthermore, miR-20a and miR-17-5p were increased in the metastatic carcinoma and six atypical pituitary adenomas as compared to eight typical pituitary adenomas as measured by quantitative real-time PCR. Both PTEN and TIMP2 were bioinformatically predicated and confirmed in vitro as target genes of these three microRNAs. As semi-quantified by immunohistochemistry, PTEN was absent and TIMP2 was decreased in the metastatic pituitary carcinoma as compared to pituitary adenomas.

Conclusions

Our results suggest microRNA involvement in malignant pituitary progression, whereby increased miR-20a, miR-106b and miR-17-5p promote metastasis by attenuating PTEN and TIMP2 in pituitary carcinoma.

Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Trouillas J et al (2004) Pituitary tumors: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Tumors of pituitary, chapter 1. Pathology and genetics of tumours of endocrine organs. World Health Organization Classification of Tumours. IARC Press, Lyon

Amar AP, Hinton DR, Krieger MD, Weiss MH (1999) Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2:117–122CrossRefPubMed

Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ et al (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(99–106):106–107

Kaltsas GA, Grossman AB (1998) Malignant pituitary tumours. Pituitary 1:69–81CrossRefPubMed

Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16:E7CrossRefPubMed

Sironi M, Cenacchi G, Cozzi L, Tonnarelli G, Iacobellis M, Trere D et al (2002) Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report. J Clin Pathol 55:148–151PubMedCentralCrossRefPubMed

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMed

Cuellar TL, McManus MT (2005) MicroRNAs and endocrine biology. J Endocrinol 187:327–332CrossRefPubMed

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866CrossRefPubMed

10.

Ma L, Weinberg RA (2008) MicroRNAs in malignant progression. Cell Cycle 7:570–572CrossRefPubMed

11.

Butz H, Liko I, Czirjak S, Igaz P, Korbonits M, Racz K et al (2011) MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary 14:112–124CrossRefPubMed

12.

Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y et al (2011) Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am J Pathol 179:2120–2130PubMedCentralCrossRefPubMed

13.

D’Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G et al (2012) Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab 97:E1128–E1138CrossRefPubMed

14.

Leone V, Langella C, D’Angelo D, Mussnich P, Wierinckx A, Terracciano L et al (2014) Mir-23b and miR-130b expression is downregulated in pituitary adenomas. Mol Cell Endocrinol 390:1–7CrossRefPubMed

15.

Palmieri D, D’Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A et al (2012) Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 31:3857–3865CrossRefPubMed

16.

Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, Stratakis CA (2013) Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 32:1651–1659PubMedCentralCrossRefPubMed

17.

Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovacs G, Korbonits M, Scheithauer BW, Kovacs K, Lloyd RV (2010) MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 38:67–75CrossRefPubMed

18.

Trivellin G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, McKay T, Patocs A, Grossman AB, Korbonits M (2012) MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. Am J Physiol Endocrinol Metab 303:E708–E719CrossRefPubMed

19.

Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257–266CrossRefPubMed

20.

Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33:e179PubMedCentralCrossRefPubMed

21.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408CrossRefPubMed

22.

Feng ZZ, Chen JW, Yang ZR, Lu GZ, Cai ZG (2012) Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression. Med Oncol 29:304–310CrossRefPubMed

23.

Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53:292–301PubMedCentralCrossRefPubMed

24.

Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4:199–227PubMedCentralCrossRefPubMed

25.

Gadelha MR, Kasuki L, Denes J, Trivellin G, Korbonits M (2013) MicroRNAs: suggested role in pituitary adenoma pathogenesis. J Endocrinol Invest 36:889–895CrossRefPubMed

26.

Fan X, Liu Y, Jiang J, Ma Z, Wu H, Liu T et al (2010) miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin 42:318–324CrossRefPubMed

27.

Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES (2012) miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72:908–916PubMedCentralCrossRefPubMed

28.

Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J et al (2013) MiR-20a triggers metastasis of gallbladder carcinoma. J Hepatol 59:518–527CrossRefPubMed

29.

Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM et al (2010) Identification of the miR-106b ~ 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3:a29CrossRef

30.

Yau WL, Lam CS, Ng L, Chow AK, Chan ST, Chan JY et al (2013) Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process. PLoS one 8:e57882PubMedCentralCrossRefPubMed

31.

Fang L, Li H, Wang L, Hu J, Jin T, Wang J et al (2014) MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 5:2974–2987PubMedCentralPubMed

32.

Carthew RW, Sontheimer EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136:642–655PubMedCentralCrossRefPubMed

33.

Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20CrossRefPubMed

34.

Cantley LC, Neel BG (1999) New insights into tumor suppression: pTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245PubMedCentralCrossRefPubMed

35.

Mayo LD, Donner DB (2002) The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 27:462–467CrossRefPubMed

36.

Yamada KM, Araki M (2001) Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114:2375–2382PubMed

37.

Zhang LL, Liu J, Lei S, Zhang J, Zhou W, Yu HG (2014) PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression. Cell Signal 26:1011–1020CrossRefPubMed

38.

Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y et al (2014) Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/beta-catenin signaling. Gene 535:191–197CrossRefPubMed

39.

Wong GS, Rustgi AK (2013) Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer 108:755–761PubMedCentralCrossRefPubMed

40.

Danilewicz M, Sikorska B, Wagrowska-Danilewicz M (2003) Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer. Med Sci Monit 9:T42–T47

41.

Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G (2000) Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 96:3064–3069PubMed

42.

DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM (1992) Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701–708PubMed

43.

Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C et al (2001) AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 12:515–526CrossRefPubMed

44.

Nuovo GJ, MacConnell PB, Simsir A, Valea F, French DL (1995) Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55:267–275PubMed

45.

Scheithauer BW, Kovacs KT, Laws EJ, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733–744CrossRefPubMed

46.

Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WJ, Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56:1066–1074PubMed

47.

Kontogeorgos G (2005) Classification and pathology of pituitary tumors. Endocrine 28:27–35CrossRefPubMed

48.

Pasquel FJ, Vincentelli C, Brat DJ, Oyesiku NM, Ioachimescu AG (2013) Pituitary carcinoma in situ. Endocr Pract 19:e69–e73CrossRefPubMed

Title: MicroRNA involvement in a metastatic non-functioning pituitary carcinoma
Authors: Zhenqing Wei
Cuiqi Zhou
Mei Liu
Yong Yao
Jian Sun
Jianqi Xiao
Wenbin Ma
Huijuan Zhu
Renzhi Wang
Publication date: 01-10-2015
Publisher: Springer US
Published in: Pituitary / Issue 5/2015
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-015-0648-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

MicroRNA involvement in a metastatic non-functioning pituitary carcinoma

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2015

Intraoperative indocyanine green videoangiography for identification of pituitary adenomas using a microscopic transsphenoidal approach

Intrasellar abscess following pituitary surgery

Primary meningeal melanocytoma of the sellar region: review of the literature and differential diagnosis with special reference to angiographical features

Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis

Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?

The infundibulo-tuberal syndrome caused by craniopharyngiomas: clinicopathological evidence from an historical French cohort (1705–1973)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page